Application of iridoid compound in preparation of medicine for treating acute lung injury or pulmonary fibrosis

A technology for iridoids and acute lung injury, which is applied in the field of medicine and can solve problems such as no iridoid glycosides

Pending Publication Date: 2021-09-07
XIAMEN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] At present, there is no relevant report on the use of iridoid glycosides for

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of iridoid compound in preparation of medicine for treating acute lung injury or pulmonary fibrosis
  • Application of iridoid compound in preparation of medicine for treating acute lung injury or pulmonary fibrosis
  • Application of iridoid compound in preparation of medicine for treating acute lung injury or pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0043] The present invention will be further described below in conjunction with the accompanying drawings and embodiments. It should be noted that the following description is only for explaining the present invention and not limiting its content.

[0044] experiment procedure

[0045] 1. 10% APS: Weigh 2 g of ammonium persulfate (APS), dissolve in 20 mL of ultrapure water, dissolve and mix with a vortex shaker, dispense into 1.5 mL EP tubes, and store at -20°C.

[0046] 2. 10% SDS: Weigh 5 g of sodium dodecyl sulfate (SDS), dissolve it in 40 mL of ultrapure water, dilute to 50 mL after complete dissolution, and store at room temperature.

[0047] 3. pH 6.8 Tris-HCl (1M): Weigh 60.57g of Tris (Tris) and dissolve it in 400mL ultrapure water, adjust the pH to 6.8 with concentrated hydrochloric acid, and dilute the ultrapure water to 500mL. Store at 4°C.

[0048] 4. pH 8.8 Tris-HCl (1.5M): Weigh 90.9g of Tris and dissolve in 400mL ultrapure water, adjust the pH value to 8.8 wi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of an iridoid compound in preparation of a medicine for treating acute lung injury or pulmonary fibrosis. The application comprises the steps that RLE-6TN and Raw264.7 are used for constructing an acute lung injury cell model, an LPS-induced mouse acute lung injury model and a bleomycin-induced mouse pulmonary fibrosis model; from the aspects of proinflammatory cytokine expression, lung histopathology, oxidation resistance, NF-kappa B/Stat3 signal channel related protein expression and the like, the protection effect and the action mechanism of the iridoid compound, especially morroniside and loganin on acute lung injury are discussed; by copying a pulmonary fibrosis model, the protection effect of loganin and morroniside on pulmonary fibrosis is preliminarily proved; and it is preliminarily proved that the protection effect of loganin and morroniside on acute lung injury is possibly achieved through an NF-kappa B/Stat3 signal channel.

Description

technical field [0001] The invention relates to a new application of iridoid compounds, in particular to the application of iridoid compounds in the preparation of drugs for treating acute lung injury or pulmonary fibrosis. It belongs to the field of medical technology. Background technique [0002] Acute lung injury (Acute lung injury, ALI) and its severe stages of acute respiratory distress syndrome (Acute respiratory distress syndrome, ARDS) and pulmonary fibrosis are relatively difficult diseases of the respiratory system, which seriously affect respiratory function and can lead to respiratory failure . [0003] Among patients with acute lung injury, a large proportion of patients with acute lung injury will experience severe mesenchymal cell proliferation, neovascularization, type I and type III collagen, and matrix deposition rich in fibronectin within 10 to 14 days of clinical manifestations. A fibroproliferative process characterized by alveolar granulation tissue....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P11/00
CPCA61K31/7048A61P11/00
Inventor 宋刚马秋娟张功业
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap